We have attached herewith intimation as per Regulation 30 of SEBI (LODR) Regulation, 2015 regarding acquisition of stake in Bizotic Life Science Private Limited.
Kindly take the same ....
M&A
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 20 Mar 2026, 01:38 PM IST · BSE ID: df366362-1253-412e-a160-c111b8b1e50d
View Original BSE Filing (PDF)
💡
In Simple Terms
Anlon Healthcare completed buying a majority stake in another company, Bizotic Life Science, making it a subsidiary.
🤖 AI Summary
- Anlon Healthcare completed acquisition of 56.67% equity stake in Bizotic Life Science Private Limited on March 20, 2026
- Share Purchase Agreement executed November 28, 2025; amendment agreement dated February 27, 2026 extended completion timeline
- Bizotic Life Science becomes subsidiary of Anlon Healthcare consequent to acquisition completion
- Transaction executed under Companies Act 2013 Section 179(3)(e) & (j) compliance framework
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shareholding Acquired
56.67%
Share Purchase Agreement Date
November 28, 2025
Acquisition Completion Date
March 20, 2026
Amendment Agreement Date
February 27, 2026
🏢 How This Affects the Company
Anlon Healthcare gains 56.67% controlling interest in Bizotic Life Science, expanding portfolio into life sciences vertical and establishing new subsidiary operations.
Balance sheet consolidates Bizotic Life Science subsidiary financials; investment value classified as per acquisition accounting standards under Companies Act 2013.
Anlon Healthcare integrates Bizotic Life Science as subsidiary entity; operational control and governance framework now consolidated under parent company oversight.
Acquisition integration risk exists during subsidiary consolidation phase; regulatory compliance framework now extends to newly acquired life sciences operations.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required. Monitor next quarterly results for subsidiary consolidated financials and management commentary on integration progress.
👤
Who Is Affected
All equity shareholders of Anlon Healthcare. Balance sheet consolidates Bizotic Life Science subsidiary from March 20, 2026; earnings and asset base expand accordingly.
🔍
Management Signal
Management has deployed capital toward vertical expansion via subsidiary acquisition; signals intent to grow life sciences operations and diversify revenue base.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q4 FY26 results — verify consolidated financials include Bizotic Life Science subsidiary contribution from March 20 onwards
FY27 results — assess integration success, subsidiary profitability, and synergy realization with parent company operations
Board announcements — monitor for management commentary on subsidiary operations, capital allocation, and strategic deployment plans
MEDIUM RISK
Integration execution risk during consolidation phase. No financial data disclosed on acquisition consideration, funding source, or target profitability metrics.
💡 Investor Takeaway
Anlon Healthcare completed acquisition of 56.67% equity shareholding in Bizotic Life Science on March 20, 2026, making it a subsidiary. Share Purchase Agreement signed November 28, 2025; completion timeline extended via February 27, 2026 amendment. Transaction follows Companies Act 2013 Section 179(3) compliance.
⚖️ Strengths & Concerns
✅ Positives
- Acquisition completed as planned within extended timeline; demonstrates execution capability and deal closure competency.
- Majority stake of 56.67% provides full operational and governance control over subsidiary operations and strategic direction.
⚠️ Concerns
- Completion deadline was extended from original target to April 02, 2026, indicating initial timeline slippage or conditions adjustment.
- Filing lacks specific financial data on acquisition consideration, valuation, or funding sources used for stake acquisition.